

FORM N-PX FILER INFORMATION	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB APPROVAL
Form N-PX	FORM N-PX ANNUAL REPORT OF PROXY VOTING RECORD	OMB Number: 3235-0582 Estimated average burden hours per response: 20.8

N-PX: Filer Information

Filer CIK:	0001388325
Filer CCC:	ot*fjs4o
Date of Report:	06/30/2026
Are you a Registered Management Investment Company or an Institutional Manager?	Institutional Manager
Filer Investment Company Type	
Is this a LIVE or TEST Filing?	LIVE
Is this an electronic copy of an official filing submitted in paper format?	☐

Submission Contact Information

Name	Toppan Merrill EDGAR Support
Phone	800-688-1933
E-mail Address	e-support@toppanmerrill.com

Notification Information

Notify via Filing Website only?	☐
Notification E-mail Address:	service@toppanmerrill.com

N-PX: Series/Class (Contract) Information

N-PX: Cover Page

Name and address of reporting person:

Name of reporting person (For registered management investment companies, provide exact name of registrant as specified in charter)	Novo Holdings A/S
Street 1	TUBORG HAVNEVEJ 19
Street 2	
City	HELLERUP
State/Country	G7
Zip code and zip code extension or foreign postal code	2900
Telephone number of reporting person, including area code:	45-3527-6500

Name and address of agent for service:

Name of agent for service	
Street 1	
Street 2	
City	
State/Country	
Zip code and zip code extension or foreign postal code	
Reporting Period:	Report for the year ended June 30, 2026
SEC Investment Company Act or Form 13F File Number:	028-16231
CRD Number (if any):	
Other SEC File Number (if any):	
Legal Entity Identifier (if any):	

Report Type (check only one):

	Registered Management Investment Company.
	☐ Fund Voting Report (Check here if the registered management investment company held one or more securities it was entitled to vote.)
	☐ Fund Notice Report (Check here if the registered management investment company did not hold any securities it was entitled to vote.)
	Institutional Manager.
	☒ Institutional Manager Voting Report (Check here if all proxy votes of this reporting manager are reported in this report.)
	☐ Institutional Manager Notice Report (Check here if no proxy votes are reported in this report and complete the notice report filing explanation section below)
	☐ Institutional Manager Combination Report (Check here if a portion of the proxy votes for this reporting manager are

Confidential Treatment Requested. (The Institutional Manager has omitted from this public Form N-PX one or more proxy vote(s) for which it is requesting confidential treatment from the U.S. Securities and Exchange Commission pursuant to the instructions of this form):

Do you wish to provide explanatory information pursuant to Special Instruction B.4?:

Additional information:

☐

reported in this report and a portion are reported by other reporting person(s).)

☐

Yes

☒

No

N-PX: Summary - Included Managers

Number of Included Institutional Managers:

0

N-PX: Signature Block

Reporting Person:

Novo Holdings A/S

By (Signature):

Barbara Fiorini

By (Printed Signature):

Barbara Fiorini

By (Title):

General Counsel

Date:

08/31/2026

FORM N-PX PROXY VOTING RECORD

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5	COLUMN 6	COLUMN 7	COLUMN 8	COLUMN 9	COLUMN 10	COLUMN 11	COLUMN 12			COLUMN 13	COLUMN 14	COLUMN 15
NAME OF ISSUER	CUSIP	ISIN	FIGI	MEETING DATE	VOTE DESCRIPTION	VOTE CATEGORY	DESCRIPTION OF OTHER CATEGORY	VOTE SOURCE	SHARES VOTED	SHARES ON LOAN	DETAILS OF VOTE			MANAGER NUMBER	SERIES ID	OTHER INFO
											HOW VOTED	SHARES VOTED	FOR OR AGAINST MANAGEMENT			
4D Molecular Therapeutics, Inc.	35104E100	US35104E1001		06/17/2026	Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay").	SECTION 14A SAY-ON-PAY VOTES			3270000	0	FOR	3270000	FOR			
Apogee Therapeutics, Inc.	037598109	US0375981091		06/09/2026	Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement.	SECTION 14A SAY-ON-PAY VOTES			450000	0	FOR	450000	FOR			
BioMarin Pharmaceutical Inc.	09061G101	US09061G1013		06/02/2026	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.	SECTION 14A SAY-ON-PAY VOTES			0	0						
Celldex Therapeutics, Inc.	15117B202	US15117B2025		06/25/2026	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.	SECTION 14A SAY-ON-PAY VOTES			1025000	0	FOR	1025000	FOR			
Crinetics Pharmaceuticals, Inc.	22663K107	US22663K1079		06/18/2026	To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	SECTION 14A SAY-ON-PAY VOTES			1345071	0	FOR	1345071	FOR			
Edgewise Therapeutics, Inc.	28036F105	US28036F1057		06/04/2026	Conduct an advisory vote on the compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			5350000	0	FOR	5350000	FOR			
Enliven Therapeutics, Inc.	29337E102	US29337E1029		06/09/2026	To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.	SECTION 14A SAY-ON-PAY VOTES			1200000	0	FOR	1200000	FOR			
Enliven Therapeutics, Inc.	29337E102	US29337E1029		06/09/2026	To approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			1200000	0	1 YEAR	1200000	FOR			
INSMED Incorporated	457669307	US4576693075		05/13/2026	An advisory vote on the 2025 compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			200000	0	FOR	200000	FOR			
LanzaTech Global, Inc.	51655R200	US51655R2004		07/28/2025	To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			0	0						
LanzaTech Global, Inc.	51655R200	US51655R2004		06/23/2026	To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			0	0						
Marqeta, Inc.	57142B104	US57142B1044		06/10/2026	To approve, on a non-binding advisory basis, the compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			441558	0	FOR	441558	FOR			
Merus N.V.	N5749R100	USN5749R1007		12/09/2025	Non-binding advisory proposal to approve certain compensation arrangements.	SECTION 14A SAY-ON-PAY VOTES			750000	0	FOR	750000	FOR			

Mirum Pharmaceuticals, Inc.	604749101	US6047491013		06/15/2026	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.	SECTION 14A SAY-ON-PAY VOTES			1125000	0	FOR	1125000	FOR			
Salesforce, Inc.	79466L302	US79466L3024		05/28/2026	Approval, on an advisory basis, of the fiscal 2026 compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			393187	0	FOR	393187	FOR			
Vaxcyte, Inc.	92243G108	US92243G1085		06/15/2026	Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.	SECTION 14A SAY-ON-PAY VOTES			800000	0	FOR	800000	FOR			
Viridian Therapeutics, Inc.	92790C104	US92790C1045		06/02/2026	To approve, on an advisory basis, the compensation of the Company's named executive officers.	SECTION 14A SAY-ON-PAY VOTES			2000000	0	FOR	2000000	FOR			
Viridian Therapeutics, Inc.	92790C104	US92790C1045		06/02/2026	To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.	SECTION 14A SAY-ON-PAY VOTES			2000000	0	1 YEAR	2000000	FOR			
Xenon Pharmaceuticals Inc.	98420N105	US98420N1054		06/02/2026	To approve, on an advisory basis, the compensation of the Corporation's named executive officers.	SECTION 14A SAY-ON-PAY VOTES			485438	0	FOR	485438	FOR			
Xenon Pharmaceuticals Inc.	98420N105	US98420N1054		06/02/2026	To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers.	SECTION 14A SAY-ON-PAY VOTES			485438	0	1 YEAR	485438	FOR			